{
  "abstract": "Mirikizumab has expanded the therapeutic landscape for moderate-to-severe ulcerative colitis (UC), with efficacy demonstrated in the LUCENT phase 3 programme. However, as with many advanced therapies, an important question remains: are fixed induction regimens sufficient for the increasingly complex patients treated in routine clinical practice?1",
  "authors": [
    {
      "affiliations": [
        "Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain"
      ],
      "name": "María Calvo Arbeloa"
    },
    {
      "affiliations": [
        "Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain"
      ],
      "name": "Iranzu Elcano Aguirre"
    },
    {
      "affiliations": [
        "Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain"
      ],
      "name": "Amaya Arrondo Velasco"
    },
    {
      "affiliations": [
        "Pharmacy Department, Hospital Universitario de Navarra, Pamplona, Navarra, Spain"
      ],
      "name": "Maite Sarobe Carricas"
    }
  ],
  "title": "Is standard induction with mirikizumab sufficient in refractory ulcerative colitis in real-world practice?",
  "uid": "f6dec900-0cb1-54dc-a8c6-28fc573fda84"
}